Modulation of Bio-electrical Rhythms Via a Novel Engineering Approach

Peak revenue. Shown for cohort consistency only — this is not the decision criterion. A biological pacemaker would have to displace a mature implantable-device standard of care: the entire global leadless-pacemaker market was ~USD 420M in 2024 and conventional pacemakers grow mid-single-digits, all reimbursed and low-cost. A successful single biological-pacemaker product capturing a niche of device-ineligible or device-explanted patients is modeled at a conservative ~USD 250M illustrative peak, well below the device market and far below an orphan-gene-therapy ceiling, because the realistic value path is licensing of the broad engineered-ion-channel method to a device/pharma developer, not standalone product economics — and the foundational patent expired 2 Aug 2025, removing the composition-of-matter exclusivity that would underpin any product peak.

WACC. 16% reflects very-early platform-method risk with no clinical proof of concept, a ~20-year preclinical track record in the closest lineage, an expired foundational patent, and a low-cost reimbursed device incumbent — well above standard cardiovascular-therapeutic risk (12%).

This is not a single drug or a clinically de-risked candidate. JHTV 24627 (Case C04506, invention reported 2004) is a foundational gene-engineering METHOD: the use of normal and engineered ion-channel proteins — the patent specifically claims modified HCN constructs, including an HCN1 with an altered S3–S4 linker that shifts activation roughly 20 mV — delivered by in vivo or ex vivo gene transfer to confer or modulate spontaneous electrical automaticity in cardiac, neuronal, and pancreatic cells (a custom-tailored 'bio-battery'). It is the Johns Hopkins-origin scientific lineage of the de novo biological-pacemaker concept Marbán pioneered around 2002–2004. It is best classified as an enabling platform / basic-mechanism method, and the rNPV envelope below is shown only for cohort consistency — the rNPV is not the decision criterion here, which is why the asset is classified as grant_non_commercial. Two facts dominate any honest read: the foundational US patent 9,480,719 EXPIRED on 2 August 2025, removing the composition-of-matter exclusivity an equity story would rest on; and the closest, furthest-advanced comparable program (the AAV/Ad-TBX18 and engineered-HCN gene-transfer work in the Marbán/Cingolani lineage) has, after ~20 years and explicit NIH 'proof-of-concept to clinic' funding, still not opened a first-in-human trial.

The economic frame follows directly from the comparators. The TBX18 and engineered-HCN gene-transfer programs anchor mechanism plausibility (autonomic-responsive ectopic automaticity is reproducible in large animals) but also anchor a punishing timeline and construct-dependent failure risk — 2025 data show AAV-TBX18 did not generate pacing and produced fibrosis at fibrogenic doses, while AAV-Hcn2 did. On the commercial side the only honest anchor is the incumbent it must displace: the entire global leadless-pacemaker market was roughly USD 420M in 2024 (Medtronic Micra ~47% share) against a mature, low-cost, fully-reimbursed conventional-device standard of care, and device innovators (e.g. the Ceryx respiratory-variable pacemaker) are already first-in-human on the 'more physiological pacing' aspiration via a far faster modality. The engine result is -$47.9M to -$26.3M, with a base rNPV of -$37.1M and cumulative PoS of 1.9%; that spread should be read as an illustrative platform envelope, not a product forecast — the realistic value path is non-exclusive licensing of the broad engineered-ion-channel method to a device or gene-therapy developer, with the originating institution capturing milestones/royalties rather than full product peak, and even that is weakened by the lapsed patent.

Verdict: a scientifically important, genuinely foundational platform method whose value is academic and licensing, not standalone-equity. It earns its rank-17 slot on the rubric's modality_pos (gene-therapy bucket), high IRA-exposure subscore, and a neutral 0.5 whitespace from an 'other' cardiovascular indication outside the supported enums — not on being a fundable product. The grant_non_commercial archetype is the correct call: with an expired foundational patent, no clinical proof of concept after two decades, and a low-cost reimbursed device incumbent, this is a licensing/credibility asset for JHTV, not a venture-equity therapeutic.